Table 4.
Association between atopy and remission of respiratory symptoms classified by the treatment group and gender
|
Respiratory symptom |
Total population |
Males |
Females |
|||
|---|---|---|---|---|---|---|
| |
OR (95% CI) of phadiatop |
OR (95% CI) of phadiatop |
OR (95% CI) of phadiatop |
|||
| Placebo | Budesonide | Placebo | Budesonide | Placebo | Budesonide | |
|
Wheezing at any time |
0.99 (0.59–1.67) |
1.18 (0.70–1.99) |
0.88 (0.48–1.60) |
1.26 (0.70–2.26) |
2.06 (0.55–7.78) |
0.51 (0.15–1.71) |
|
Cough day/night or in a.m. |
0.85 (0.53–1.36) |
1.93 (1.11–3.37)*,$ |
0.87 (0.52–1.45) |
1.94 (1.05–3.57)* |
0.79 (0.26–2.41) |
1.84 (0.47–7.30) |
|
Phlegm in day/night or in a.m. |
1.21 (0.72–2.03) |
1.67 (0.99–2.82)# |
1.14 (0.65–2.00) |
1.63 (0.93–2.87)# |
1.48 (0.34–6.45) |
1.53 (0.28–8.26) |
|
Trouble with breathing |
0.84 (0.48–1.47) |
1.76 (0.99–3.11)# |
0.96 (0.50–1.82) |
2.76 (1.45–5.26)*,$ |
0.47 (0.18–1.21) |
0.43 (0.17–1.12)# |
|
Woken with chest tightness |
2.18 (0.97–4.90)# |
2.32 (0.60–8.91) |
2.17 (0.67–6.99) |
1.33 (0.22–7.85) |
5.76 (1.67–19.86)* |
8.82 (0.63–123.66) |
| Attack of dyspnea after activity | 1.01 (0.52–1.95) | 1.11 (0.63–1.96) | 1.04 (0.49–2.20) | 0.87 (0.46–1.64) | 1.03 (0.29–3.63) | 3.67 (0.68–19.70) |
*OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarette and FEV1 % pred.
#Trend (0.05 < p. value < 0.1). $Interaction between Phadiatop and treatment group has a p.value < 0.05.